


Idorsia Company Profile

Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.

We may be young, but we have a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of over 1,200 professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.

- Company Profile
- > Financial overview 
- Company strategy
- Innovation portfolio
- Partnerships
- Company milestones

Financial overview	First Half			
	US GAAP		Non-GAAP*	
in CHF millions, except EPS (CHF) and number of shares (millions)	2023	2022	2023	2022
Net revenues	51	22	51	22
Operating expenses	(426)	(427)	(393)	(407)
Operating income (loss)	(375)	(405)	(342)	(384)
Net income (loss)	(405)	(419)	(369)	(395)
Basic EPS	(2.28)	(2.36)	(2.07)	(2.23)
Basic weighted average number of shares	178.1	177.3	178.1	177.3
Diluted EPS	(2.28)	(2.36)	(2.07)	(2.23)
Diluted weighted average number of shares	178.1	177.3	178.1	177.3

The full financial statements can be found in the Financial Report available on our corporate website.

* Idorsia measures, reports and issues guidance on non-GAAP operating performance. Idorsia believes that these non-GAAP financial measurements more accurately reflect the underlying business performance and therefore provide useful supplementary information to investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.

Share Information

Idorsia was incorporated in March 2017 and listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017.

Idorsia Ltd is part of the following indices: SPI, SPIEX, SPI ESG, SXSLI, SXI Life Sciences, SXI Bio+Medtech, and SSIRT.

Idorsia is traded under the following symbols:
Reuters IDIA.S / Bloomberg IDIA:SW.

Company Strategy

We will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. We have identified five key strategic priorities to ensure the company's success going forward.

Advance late-stage pipeline

We believe that our development compounds have the potential to significantly change treatment in their target diseases, resulting in medicines with substantial commercial potential.

Successfully launch our new products

In order to successfully bring our pioneering therapies to patients and to maximize the value of our innovations, we will continue to build and strengthen our global commercial organization.

Bring Idorsia to sustainable profitability

We are building Idorsia with a long-term focus and ambitious aspirations. By advancing our development pipeline and successfully launching our first products, we aim to bring Idorsia to sustainable profitability as soon as possible.

Fuel our pipeline with new discoveries

While launching our first marketed products and developing our late-stage clinical pipeline to bring our innovative therapies to patients, we also continue to discover new compounds.

Utilize state-of-the-art technologies to drive innovation

As we wish to remain at the cutting edge of science, it is vital that we consider innovative approaches and utilize state-of-the-art technologies at each stage of the process, from bench to bedside.

Company Profile

Financial overview

> Company strategy

Innovation portfolio

Partnerships

Company milestones

Innovation portfolio

Product / compound	Mechanism of action	Therapeutic area	Status
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Commercially available in the US, Germany, Italy, and Switzerland; approved in the EU, UK, and Canada; Filing in Japan expected H2 2023; Phase 2 in pediatric insomnia – recruiting
Aprocitentan*	Dual endothelin receptor antagonist	Difficult-to-control (resistant) hypertension	NDA under review in the US, MAA under review in the EU, other filings in preparation
Lucerastat	Glucosylceramide synthase inhibitor	Fabry disease	Phase 3 primary endpoint not met, Open Label Extension (OLE) study ongoing
Selatogrel	P2Y ₁₂ inhibitor	Suspected acute myocardial infarction	Phase 3 recruiting
Cenerimod	S1P ₁ receptor modulator	Systemic lupus erythematosus	Phase 3 recruiting
ACT-1004-1239	ACKR3 / CXCR7 antagonist	Multiple sclerosis and other demyelinating diseases	Phase 2 in preparation
Sinbaglustat	GBA2/GCS inhibitor	Rare lysosomal storage disorders	Phase 1 complete
ACT-1014-6470	C5aR1 antagonist	Immune-mediated disorders	Phase 1
ACT-777991	CXCR3 antagonist	Recent-onset Type 1 diabetes	Phase 1
IDOR-1117-2520	Undisclosed	Immune-mediated disorders	Phase 1
IDO-090	Synthetic glycan vaccine	<i>Clostridium difficile</i> infection	Phase 1 in preparation

**In collaboration with Janssen Biotech.*

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 was investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy. The study did not meet the primary endpoint. ACT-709478 was generally well tolerated. Neurocrine continues to analyze the data generated in the study.

On July 20, 2023, Idorsia sold its operating businesses in the Asia Pacific (ex-China) region to Sosei Heptares, including the assignment of the license for PIVLAZ (clazosentan) for the Asia Pacific (ex-China) region. Idorsia retains the rights to clazosentan in the rest of the world.

Company Profile

Financial overview

Company strategy

> Innovation portfolio

Partnerships

Company milestones

Partnerships

Halozyme

In 2019, Idorsia entered into a global agreement with Halozyme to develop a novel drug-device product combining selatogrel – Idorsia’s potent, fast-acting, reversible and highly selective P2Y₁₂ inhibitor – with Halozyme’s subcutaneous QuickShot® auto-injector. In 2021, Idorsia initiated the Phase 3 study SOS-AMI with the selatogrel drug-device for the treatment of suspected acute myocardial infarction. www.halozyme.com

Mochida

In 2019, Idorsia and Mochida Pharmaceutical entered into an exclusive license agreement for the supply, co-development and co-marketing of Idorsia’s daridorexant for insomnia and related disorders in Japan. www.mochida.co.jp

Neurocrine

In 2020, Idorsia entered into a global license agreement with Neurocrine Biosciences for the development and commercialization of ACT-709478, Idorsia’s novel T-type calcium channel blocker. ACT-709478 was investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy. The study did not meet the primary endpoint. ACT-709478 was generally well tolerated. Neurocrine continues to analyze the data generated in the study to determine the next steps. In addition, a research collaboration was established to discover, identify, and develop additional novel T-type calcium channel blockers. www.neurocrine.com

Santhera

In 2020, Idorsia’s license, collaborative development and commercialization agreement with ReveraGen BioPharma in respect of vamorolone was transferred in its entirety to Santhera Pharmaceuticals, with the latter replacing Idorsia as a party to the agreement. Idorsia will be entitled to development and sales milestones, as well as low single-digit percentage payments on net sales of vamorolone. www.santhera.com

Syneos Health

In 2020, Idorsia and Syneos Health entered into an innovative commercial partnership to build the salesforce for the US launch of QUVIVIQ (daridorexant). In January 2022, Idorsia expanded this commercialization partnership to support the launch of QUVIVIQ and effectively reach the primary care market in Europe and Canada. www.syneoshealth.com

Simcere

In 2022, Idorsia and Simcere entered into an exclusive licensing agreement for Idorsia’s daridorexant in China. Under the agreement, Simcere has an exclusive right to develop and commercialize daridorexant in the Greater China region. en.simcere.com

Sosei Heptares

In 2023, Idorsia and Sosei Heptares entered into a co-exclusive license agreement for daridorexant in the Asia Pacific (ex-China) region*. In addition, Idorsia granted an option for Sosei Heptares to license cenerimod and lucerastat for the development and commercialization, and a right of first negotiation and right of first refusal on certain other pipeline assets in the region. www.soseiheptares.com

* Australia, Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and Vietnam

Company Profile

Financial overview

Company strategy

Innovation portfolio

> Partnerships

Company milestones

Company milestones

2023

June QUVIVIQ (daridorexant) launched in Switzerland

April QUVIVIQ (daridorexant) approved in Canada

January MAA for apocitentan submitted to the EMA for the treatment of patients with resistant hypertension

2022

December NDA for apocitentan submitted to the US FDA for the treatment of patients with difficult-to-control hypertension

December OPUS Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus initiated

November QUVIVIQ (daridorexant) launched in Germany and Italy

November The Lancet and American Heart Association (AHA) late-breaking science session reports significant and sustained effect of apocitentan on lowering blood pressure for patients with resistant hypertension

May Europe's first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

May QUVIVIQ (daridorexant) 25 mg and 50 mg launched in the US for the treatment of adults with insomnia

January The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

Company Profile

Financial overview

Company strategy

Innovation portfolio

Partnerships

> Company milestones

2021

December Idorsia to further characterize lucerastat for Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

September Five Idorsia affiliates in key European markets (France, Germany, Italy, Spain, UK) established

June Initiation of Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

2020

July Establishment of Idorsia Pharmaceuticals US Inc. to perform commercial operations

May Global license agreement with Neurocrine Biosciences for the development and commercialization of ACT-709478

2019

November Collaboration Agreement with Halozyme for the development of a novel self-administered drug-device product for selatogrel

2017

June Idorsia opens its doors and is listed on SIX Swiss Stock Exchange

Company Profile

Financial overview

Company strategy

Innovation portfolio

Partnerships

> Company milestones



Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. It is headquartered in Allschwil/Basel, Switzerland and is quoted on the SIX Swiss Exchange (tickersymbol: IDIA). All trademarks are legally protected by their respective owners.

Disclaimer This fact sheet has the sole purpose to provide members of the public with general information about the activities of Idorsia. The forward-looking statements in this fact sheet are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties.

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91
4123 Allschwil
Switzerland

investor.relations@idorsia.com
Phone +41 58 844 10 10
www.idorsia.com



**Company
Profile**

Latest update:
September 2023
Copyright © 2023 Idorsia